|Systematic (IUPAC) name|
|Licence data||US FDA:|
|(what is this?)|
Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.
Rilonacept was given an "Orphan Drug" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease(not approved in the U.S. on this indication).
On May 8th, 2012 an FDA Advisory Panel voted 11-0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.
- http://ard.bmj.com/cgi/content/short/ard.2009.108936v1?rss=1 "The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study " Oct 2009
- "Molecule of the month. Rilonacept". Drug News Perspect. 21 (4): 232. May 2008. PMID 18560622.
- "Arcalyst FDA Approval History - Drugs.com". Retrieved 2012-05-08.
- "Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today". Retrieved 2012-05-08.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|